Abstract
Multiple sclerosis (MS) is an autoimmune disease of the central nervous system and current MS treatment is only partially effective. Recent data suggest that statins may be potent immunomodulatory agents. In order to evaluate their role in MS, we analyzed the in vitro effects of interferon (IFN)-β and lovastatin on the differentiation and maturation of monocyte-derived dendritic cells (DCs) of MS patients. Twenty-seven patients with relapsing–remitting MS were recruited for the study. DC differentiation and maturation were evaluated based on surface phenotypic changes and the expressions of CD14, CD83, CD1a, CD80, CD86, CD206, and C209 were analyzed by flow cytometry. The results showed that IFN-β and lovastatin affect DC phenotype. Both agents decrease the expression of CD1a, which indicates a weakened presentation of glycolipid antigens. IFN-β causes up-regulated and lovastatin down-regulated expression of CD86, which results in a biased Th-cell responses in MS. Furthermore, high doses of lovastatin cause a decrease in CD209 expression on the surface of DCs and can limit their migration to various tissues. One of the mechanisms of the beneficial action of IFN-β and statins may be associated with their influence on DCs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Adorini L, Penna G, Giarratana N et al (2004) Dendritic cells as key targets for immunomodulation by Vitamin D receptor ligands. J Steroid Biochem Mol Biol 89–90:437–441
Birnbaum G, Cree B, Altafullah I et al (2008) Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71:1390–1395
Cella M, Sallusto F, Lanzavecchia A (1997) Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9:10–16
Geijtenbeek TB, Torensma R, van Vliet SJ et al (2000) Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses. Cell 100:575–585
Ghittoni R, Napolitani G, Benati D et al (2006) Simvastatin inhibits the MHC class II pathway of antigen presentation by impairing Ras superfamily GTPases. Eur J Immunol 36:2885–2893
Hohlfeld R, Meinl E, Weber F et al (1995) The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology 45(Suppl 6):S33–S38
Huang YM, Adikari S, Bave U et al (2005) Multiple sclerosis: interferon-beta induces CD123(+)BDCA2- dendritic cells that produce IL-6 and IL-10 and have no enhanced type I interferon production. J Neuroimmunol 158:204–212
Hussien Y, Sanna A, Soderstrom M et al (2001) Glatiramer acetate and IFN-beta act on dendritic cells in multiple sclerosis. J Neuroimmunol 121:102–110
Johnson-Anuna LN, Eckert GP, Keller JH et al (2005) Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther 312:786–793
Kuchroo VK, Das MP, Brown JA et al (1995) B7–1 and B7–2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80:707–718
Kwak B, Mulhaupt F, Myit S et al (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399–1402
Luft T, Pang KC, Thomas E et al (1998) Type 1 IFNs enhance the terminal differentiation of dendritic cells. J Immunol 161:1947–1953
Markovic-Plese S, Singh AK, Singh I (2008) Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair. Future Neurol 3:153–167
McDonald W, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121–127
Nath N, Giri S, Prasad R et al (2004) Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 172:1273–1286
Neuhaus O, Strasser-Fuchs S, Fazekas F et al (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59:990–997
Paul F, Waiczies S, Wuerfel J et al (2008) Oral high-dose atorvastatin treatment in relapsing–remitting multiple sclerosis. PLoS One 3:e1928
Porcelli SA, Modlin RL (1999) The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu Rev Immunol 17:297–329
Rudick RA, Pace A, Rani MR et al (2009) Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 72:1989–1993
Serafini B, Rosicarelli B, Magliozzi R et al (2006) Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J Neuropathol Exp Neurol 65:124–141
Then Bergh F, Dayyani F, Ziegler-Heitbrock L (2004) Impact of type-I-interferon on monocyte subsets and their differentiation to dendritic cells. An in vivo and ex vivo study in multiple sclerosis patients treated with interferon-beta. J Neuroimmunol 146:176–188
Tsakiri A, Tsiantoulas D, Frederiksen J et al (2010) Increased immunopotency of monocyte derived dendritic cells from patients with optic neuritis is inhibited in vitro by simvastatin. Exp Neurol 221:320–328
Vieira PL, Heystek HC, Wormmeester J et al (2003) Glatiramer acetate (copolymer-1, copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 170:4483–4488
Yilmaz A, Reiss C, Tantawi O et al (2004) HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis. Atherosclerosis 172:85–93
Yilmaz A, Reiss C, Weng A et al (2006) Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol 79:529–538
Youssef S, Stuve O, Patarroyo JC et al (2002) The HMGCoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78–84
Zang YC, Skinner SM, Robinson RR et al (2004) Regulation of differentiation and functional properties of monocytes and monocyte-derived dendritic cells by IFN in multiple sclerosis. Mult Scler 10:499–506
Zhang X, Jin J, Peng X et al (2008) Simvastatin inhibits IL-17 secretion by targeting multiple IL-17-regulatory cytokines and by inhibiting the expression of IL-17 transcription factor RORC in CD4+ lymphocytes. J Immunol 180:6988–6996
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Bartosik-Psujek, H., Tabarkiewicz, J., Pocinska, K. et al. Immunomodulatory Effects of IFN-β and Lovastatin on Immunophenotype of Monocyte-Derived Dendritic Cells in Multiple Sclerosis. Arch. Immunol. Ther. Exp. 58, 313–319 (2010). https://doi.org/10.1007/s00005-010-0084-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00005-010-0084-z